

Supplementary Table 5. Results of univariate and multivariate analyses of factors associated with OS of 22 patients with brainstem glioblastoma

Variable	Univariate analysis		Multivariate analysis		
	<i>p</i>	HR	95% CI	Median OS (months)	<i>p</i>
Age (≥55 years vs. <55 years)	0.666				
Sex (female vs. male)	0.397				
KPS (≥70 vs. <70)	0.132				0.091
Course of disease (≥3 months vs. <3 months)	0.192				0.137
Diameter (≥2 cm vs. <2 cm)	0.045				0.399
Location (pons vs. midbrain vs. medulla)	0.730				
Tumor Enhancement (yes vs. no)	0.007	5.647	1.517–21.013	7.8 vs. 12.5	0.010
<i>IDH</i> (mutant vs. wild type)	0.678				
<i>MGMT</i> promoter (methylated vs. unmethylated)	0.892				
1p/19q (LOH vs. intact)	0.315/0.525				
<i>TERT</i> promoter (mutant vs. wild type)	0.214				
<i>TP53</i> (mutant vs. wild type)	0.883				
<i>PTEN</i> (mutant vs. wild type)	0.016				0.548
<i>NF1</i> (mutant vs. wild type)	0.329				
<i>PIK3CA</i> (mutant vs. wild type)	0.882				
<i>EGFR</i> amplification (yes vs. no)	0.390				

CI: condence interval, HR: hazard ratio, KPS: Karnofsky performance status, LOH: loss of heterozygosity, OS: overall survival.